Teva Pharmaceutical Industries (LTS:0LER) Cyclically Adjusted FCF per Share: $1.07 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LER Teva Pharmaceutical Industries Ltd LTS:0LER
45 GF Score
Price $35.60
GF Value $20.76
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries Cyclically Adjusted FCF per Share?

Teva Pharmaceutical Industries LTS:0LER +6.27% 45 Cyclically Adjusted FCF per Share is $1.07 as of Jun. 2026. GuruFocus rates LTS:0LER with a GF Score™ of 45/100 and a GF Value™ of $20.76 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Teva Pharmaceutical Industries's adjusted free cash flow per share for the three months ended in Jun. 2026 was $0.264. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.07 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Teva Pharmaceutical Industries's average Cyclically Adjusted FCF Growth Rate was -32.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -20.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -14.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Teva Pharmaceutical Industries was 42.80% per year. The lowest was -20.70% per year. And the median was 11.25% per year.

As of today (2026-08-02), Teva Pharmaceutical Industries's current stock price is $35.60. Teva Pharmaceutical Industries's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $1.07. Teva Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF of today is 33.27.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Teva Pharmaceutical Industries was 33.97. The lowest was 1.99. And the median was 5.17.


Teva Pharmaceutical Industries  (LTS:0LER) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Teva Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=35.60/1.07
=33.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Teva Pharmaceutical Industries was 33.97. The lowest was 1.99. And the median was 5.17.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Teva Pharmaceutical Industries Cyclically Adjusted FCF per Share Related Terms


Teva Pharmaceutical Industries Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries Cyclically Adjusted FCF per Share Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 2.24 2.00 1.61 1.23

Teva Pharmaceutical Industries Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.40 1.31 1.23 1.06 1.07

LTS:0LER vs ZTS, UTHR, VTRS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Cyclically Adjusted Price-to-FCF falls into.


LTS:0LER
45GF Score
Teva Pharmaceutical Industries Ltd LTS:0LER
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Teva Pharmaceutical Industries's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.264/333.9520*333.9520
=0.264

Current CPI (Jun. 2026) = 333.9520.

Teva Pharmaceutical Industries Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 1.260 241.428 1.743
201612 -0.239 241.432 -0.331
201703 -0.065 243.801 -0.089
201706 0.238 244.955 0.324
201709 0.573 246.819 0.775
201712 0.583 246.524 0.790
201803 1.307 249.554 1.749
201806 0.026 251.989 0.034
201809 0.277 252.439 0.366
201812 0.150 251.233 0.199
201903 -0.012 254.202 -0.016
201906 -0.310 256.143 -0.404
201909 0.143 256.759 0.186
201912 0.384 256.974 0.499
202003 0.161 258.115 0.208
202006 0.129 257.797 0.167
202009 0.150 260.280 0.192
202012 0.142 260.474 0.182
202103 -0.501 264.877 -0.632
202106 0.095 271.696 0.117
202109 0.345 274.310 0.420
202112 0.275 278.802 0.329
202203 -0.186 287.504 -0.216
202206 -0.004 296.311 -0.005
202209 0.376 296.808 0.423
202212 0.747 296.797 0.841
202303 -0.255 301.836 -0.282
202306 0.183 305.109 0.200
202309 -0.127 307.789 -0.138
202312 0.952 306.746 1.036
202403 -0.221 312.332 -0.236
202406 0.005 314.175 0.005
202409 0.481 315.301 0.509
202412 0.393 315.605 0.416
202503 -0.200 319.799 -0.209
202506 0.113 322.561 0.117
202509 0.200 324.800 0.206
202512 0.867 324.054 0.893
202603 -0.176 330.213 -0.178
202606 0.264 333.952 0.264

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $1.07 mean?
Teva Pharmaceutical Industries (LTS:0LER) has a Cyclically Adjusted FCF per Share of $1.07 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Teva Pharmaceutical Industries and its competitors.
Is Teva Pharmaceutical Industries' Cyclically Adjusted FCF per Share too high?
Teva Pharmaceutical Industries' current Cyclically Adjusted FCF per Share is $1.07. Overall, Teva Pharmaceutical Industries has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Cyclically Adjusted FCF per Share compare to ZTS and UTHR?
Teva Pharmaceutical Industries' Cyclically Adjusted FCF per Share of $1.07 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Teva Pharmaceutical Industries and its competitors. Teva Pharmaceutical Industries's current Cyclically Adjusted FCF per Share is $1.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (LTS:0LER) is currently considered Significantly Overvalued. The stock's GF Value™ is $20.76, compared to a current price of $35.60 — trading 71.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $1.07. Teva Pharmaceutical Industries' overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Teva Pharmaceutical Industries (LTS:0LER), the current Cyclically Adjusted FCF per Share is $1.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (LTS:0LER) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of $35.60 is trading 71.5% above its estimated GF Value™ of $20.76. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for LTS:0LER:

  • Cyclically Adjusted FCF per Share: $1.07
  • GF Value™: $20.76 vs. price of $35.60 (71.5% above fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the LTS:0LER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
45GF Score

Get the complete analysis for LTS:0LER

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.60
Price
$20.76
GF Value